Kiniksa Pharmaceuticals, Ltd. (KNSA)
Market Cap | 1.31B |
Revenue (ttm) | 301.77M |
Net Income (ttm) | 8.65M |
Shares Out | 71.08M |
EPS (ttm) | 0.12 |
PE Ratio | 155.58 |
Forward PE | 197.88 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 398,893 |
Open | 18.10 |
Previous Close | 18.00 |
Day's Range | 18.51 - 18.90 |
52-Week Range | 13.56 - 22.09 |
Beta | 0.33 |
Analysts | Strong Buy |
Price Target | 30.20 (+61.76%) |
Earnings Date | Jul 23, 2024 |
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter... [Read more]
Financial Performance
In 2023, KNSA's revenue was $270.26 million, an increase of 22.74% compared to the previous year's $220.18 million. Earnings were $14.08 million, a decrease of -92.32%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $30.2, which is an increase of 61.76% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/8/a/press15-2481874.jpg)
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activi...
![](https://cdn.snapi.dev/images/v1/w/t/conf15-2462426.jpg)
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual G...
![](https://cdn.snapi.dev/images/v1/d/g/conf3-2416048.jpg)
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2...
![](https://cdn.snapi.dev/images/v1/v/y/press19-2385044.jpg)
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abipr...
![](https://cdn.snapi.dev/images/v1/y/i/conf2-2374499.jpg)
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:...
![](https://cdn.snapi.dev/images/v1/f/6/press10-2351720.jpg)
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
– Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart developmen...
![](https://cdn.snapi.dev/images/v1/u/g/press4-2298135.jpg)
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
![](https://cdn.snapi.dev/images/v1/o/i/conf12-2286937.jpg)
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 a...
![](https://cdn.snapi.dev/images/v1/n/h/press11-2216135.jpg)
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST ® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –
![](https://cdn.snapi.dev/images/v1/w/p/conf3-2213751.jpg)
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, J...
![](https://cdn.snapi.dev/images/v1/e/b/press13-2129965.jpg)
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –
![](https://cdn.snapi.dev/images/v1/h/c/conf12-2118334.jpg)
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8...
![](https://cdn.snapi.dev/images/v1/3/l/press20-1985970.jpg)
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the m...
![](https://cdn.snapi.dev/images/v1/q/y/conf14-1973638.jpg)
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30...
![](https://cdn.snapi.dev/images/v1/w/t/conf2-1923626.jpg)
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual G...
![](https://cdn.snapi.dev/images/v1/n/a/press6-1865101.jpg)
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growt...
![](https://cdn.snapi.dev/images/v1/q/q/conf9-1863965.jpg)
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a...
![](https://cdn.snapi.dev/images/v1/m/3/press3-1774105.jpg)
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively –
![](https://cdn.snapi.dev/images/v1/u/y/conf10-1772964.jpg)
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at...
![](https://cdn.snapi.dev/images/v1/m/x/conf17-1693707.jpg)
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, J...
![](https://cdn.snapi.dev/images/v1/8/a/conf13-1657439.jpg)
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities ...
![](https://cdn.snapi.dev/images/v1/j/n/conf11-1650276.jpg)
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual Hea...
![](https://cdn.snapi.dev/images/v1/5/y/press13-1610068.jpg)
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...
![](https://cdn.snapi.dev/images/v1/p/f/conf11-1608956.jpg)
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at ...
![](https://cdn.snapi.dev/images/v1/3/k/press6-1539941.jpg)
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological ...